13-chlorine-3,15-dioxy-gibberellic acid methyl ester

01/01/2019 - "The xenograft experiment revealed that tumor weight and volume were significantly decreased after GA-13315 3 mg/kg and 9 mg/kg (P < 0.05) treatment, and GA-13315 had low toxicity in bone marrow, kidney and colon tissues. "
01/01/2019 - "A xenograft model of A549 was established to evaluate the anti-tumor effect and histopathological examination was performed to assess the toxicity of GA-13315. "
02/01/2012 - "Cytotoxicity assays showed that GA-13315 was a potential and efficient antitumor compound, with inhibitory concentration 50 (IC(50)) values ranging from 0.13 to 30.28 μg/ml in 12 human tumor cell lines, and it showed moderate toxicity to peripheral blood mononuclear cells with an IC(50) value of 14.2 μg/ml. Administration of 0.5 or 2.5 mg/kg GA-13315 for 23 days significantly inhibited tumor growth of human non-small cell lung tumor (A549) xenografts, with relative growth rates ranging from 29.91% to 35.05%. "
01/01/2016 - "Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1."
01/01/2019 - "Anti-tumor effects and mechanism of GA-13315, a novel gibberellin derivative, in human lung adenocarcinoma: an in vitro and in vivo study."

08/01/2017 - "The present study describes the effects and mechanism of GA-13315 on the proliferation and apoptosis of KB cells in oral cancer. "
08/01/2017 - "GA-13315 can accelerate the apoptosis of oral cancer cells and presents a dose correlation. "
08/01/2017 - "According to results from the Transwell migration assay, the invasiveness of the KB cells of oral cancer were weakened after being treated by GA-13315. "
08/01/2017 - "KB cells were isolated from patients with oral cancer and treated with GA-13315 (5 µM). "
08/01/2017 - "Effects and mechanism of GA-13315 on the proliferation and apoptosis of KB cells in oral cancer."

01/01/2019 - "This study suggests that GA-13315 can be considered as a promising chemotherapeutic agent with anticancer activity in treatment of lung cancer in future."

01/01/2019 - "Anti-tumor effects and mechanism of GA-13315, a novel gibberellin derivative, in human lung adenocarcinoma: an in vitro and in vivo study."

01/01/2022 - "Gibberellin derivative GA-13315 overcomes multidrug resistance in breast cancer by up-regulating BMP6 expression."
12/01/2020 - "Chronic exposure to the gibberellin derivative GA-13315 sensitizes breast cancer MCF-7 cells but not colon cancer HCT116 cells to irinotecan."